SHIFT AI Newsroom · GLOBAL
Research Study Investigates CagriSema and Semaglutide for Weight Loss in Obesity
A new study is looking at how two different doses of CagriSema and one dose of Semaglutide can help people with obesity, with or without type 2 diabetes, lose weight.
A new research study, registered on ClinicalTrials.gov, is investigating the efficacy of two different doses of CagriSema and one dose of Semaglutide in helping people with obesity, with or without type 2 diabetes, lose weight. The study aims to provide new insights into the treatment of obesity and potentially lead to new treatment options.
What this means in the UK
This study may provide new insights into the treatment of obesity, a major health concern in the UK, and potentially lead to new treatment options for those affected.
Known facts
- A research study is investigating the efficacy of two different doses of CagriSema and one dose of Semaglutide in helping people with obesity, with or without type 2 diabetes, lose weight.